Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Fiche publication
Date publication
décembre 2022
Journal
JAMA network open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Dr DESMOULINS Isabelle
Tous les auteurs :
Carausu M, Carton M, Diéras V, Petit T, Guiu S, Gonçalves A, Augereau P, Ferrero JM, Levy C, Ung M, Desmoulins I, Debled M, Bachelot T, Pistilli B, Frenel JS, Mailliez A, Chevrot M, Cabel L
Lien Pubmed
Résumé
Evidence suggests that patients with human epidermal growth factor receptor 2-positive (ERBB2+ [formerly HER2+]) metastatic breast cancer (MBC) have different clinical characteristics and outcomes according to their hormone receptor (HR) status. The place of endocrine therapy (ET) for patients with HR+/ERBB2+ is still not clearly defined in this setting.
Référence
JAMA Netw Open. 2022 12 1;5(12):e2247154